Literature DB >> 11247329

Lack of association between antiphospholipid antibody and WHO classification in lupus nephritis.

C Fofi1, M J Cuadrado, T Godfrey, I Abbs, M A Khamashta, G R Hughes.   

Abstract

OBJECTIVE: To study the prevalence of antiphospholipid antibody (aPL) in patients with biopsy proven lupus nephritis (LN) and to investigate if there is any association between the presence of serum aPL and WHO classes.
METHODS: Seventy-one patients (68 female and 3 male, mean age 31 years, range 10-67) meeting ACR criteria for the classification of SLE and with biopsy proven LN were included. For every patient, we evaluated anticardiolipin antibodies, lupus anticoagulant and renal biopsy classified according to the WHO classification criteria (activity and chronicity scores were included). Twenty-four hour urinary protein at the time of biopsy was considered.
RESULTS: Twenty-nine patients had class V LN, 27 had class IV, 11 had class III, 3 had class II and 1 had class I. Twenty-seven (40.2%) patients were aPL positive. The prevalence of aPL positive patients was 45% in class V, 33.3% in class IV and 45.6% in class III. We did not find any significant association between the presence of aPL and the WHO class (p = 0.61 with class V, p = 0.31 with class IV and p = 0.73 with class III). There was no association between the presence of aPL and activity (p = 0.52) or chronicity scores (p = 0.42). We also did not find any association between proteinuria and the presence of aPL (p = 0.3).
CONCLUSIONS: Our results suggest that there is no association between the presence of aPL and the different WHO classes. The presence of these antibodies does not seem to be related to histological activity or the chronicity of lupus nephritis nor proteinuria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11247329

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  5 in total

1.  Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients.

Authors:  Renato Alberto Sinico; Ilaria Cavazzana; Monica Nuzzo; Monica Vianelli; Pietro Napodano; Patrizia Scaini; Angela Tincani
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 8.237

2.  Antiphospholipid antibodies in patients with proliferative and membranous lupus nephritis.

Authors:  Xiaokai Ding; Chaosheng Chen; Ji Zhang; Guoyuan Lu
Journal:  Clin Rheumatol       Date:  2020-01-13       Impact factor: 2.980

Review 3.  Renal involvement in antiphospholipid syndrome.

Authors:  Savino Sciascia; Maria José Cuadrado; Munther Khamashta; Dario Roccatello
Journal:  Nat Rev Nephrol       Date:  2014-03-18       Impact factor: 28.314

4.  Antiphospholipid Antibodies in Lupus Nephritis.

Authors:  Ioannis Parodis; Laurent Arnaud; Jakob Gerhardsson; Agneta Zickert; Birgitta Sundelin; Vivianne Malmström; Elisabet Svenungsson; Iva Gunnarsson
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

5.  The impact of antiphospholipid antibodies in children with lupus nephritis.

Authors:  Sulaiman M Al-Mayouf; Alhanouf AlSaleem; Turki Al-Hussain; Abdullah Al Sonbul; Hadeel AlMana
Journal:  Int J Pediatr Adolesc Med       Date:  2015-11-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.